๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
NCT06783647Advanced Solid Tumour
DrugsPemetrexed Disodium·LBL-024·Carboplatin·Paclitaxel
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsSonrotoclax·Obinutuzumab·Rituximab·Venetoclax
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568Endometrial Cancer
DrugsDoxorubicin·Paclitaxel
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Recruiting
Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin
NCT07106957Erythematous Telangiectatic Rosacea
Beijing Sino-German Union Cosmetic Institute Co., Ltd.
Not applicable
72
Beijing
2025-06-10
Recruiting
Non-pharmacologial, Non-invassive Intervention Before Cardiac Surgery: a Randomized Controlled Trial
NCT06791551Cardiac Surgery
China National Center for Cardiovascular Diseases
Not applicable
200
Beijing
2025-06-10
Recruiting
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
NCT07014150Hepatocellular Carcinoma Resectable
DrugsIparomlimab and Tuvonralimab·Lenvatinib
Peking Union Medical College Hospital
Phase 2
33
Beijing
2025-06-10
Recruiting
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury
NCT06954740Acute Kidney Injury
DrugAmimestrocel
Chinese PLA General Hospital
Phase 2
50
Beijing
2025-06-10
Not yet open
Safety and Effectiveness of Unilateral MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor
NCT07006740Essential Tremor
meishanshan
Observational
100
Beijing
2025-06-10
Not yet open
Telitacicept for the Treatment of Refractory RA
NCT07008196Rheumatoid Arthritis (RA)
DrugTelitacicept
Chinese SLE Treatment And Research Group
Phase 4
30
Beijing
2025-06-10
Not yet open
Azole Susceptibility and Resistance Mechanisms Surveys in Pathogenic Fungi by the CARST-fungi (2023-2024)
NCT06969703Fungal Disease
Peking University First Hospital
Observational
30
Beijing
2025-06-10
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
Beijing, Fuzhou, Guangzhou, Shandong, Shanghai
2025-06-10
Recruiting
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
NCT06969807Diabetic Kidney Disease (DKD)
DrugAmimestrocel
Chinese PLA General Hospital
Phase 2
120
Beijing
2025-06-09
Recruiting
A Real-World Study on Ultrasound-Based Screening and Integrated Therapeutic Strategies for Patients With Concomitant Coronary and Cervicocephalic Artery Stenosis
NCT07034157Coronary Artery Disease, Carotid Artery Stenosis, Cerebrovascular Disorders
Beijing Anzhen Hospital
Observational
1,000
Beijing
2025-06-09
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugBI 1291583
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615Non Small Cell Lung Cancer
DrugsHLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
243
Beijing
2025-06-09
Recruiting
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
NCT07016802Safety, Tolerability, Adult Growth Hormone Deficiency
DrugsGenSci134·Norditropin·Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
64
Beijing
2025-06-09
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
DrugIrafamdastat
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
Temporal Interference for Essential Tremor
NCT07016425Essential Tremor
Liankun_Ren
Not applicable
10
Beijing
2025-06-09
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569Chronic Hepatitis B
DrugsHepatitis B vaccine·PEG-IFNฮฑ·AHB-137
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
NCT07149831Prostate Cancer
DrugFlotufolastat F-18
Sinotau Pharmaceutical Group
Phase 1
6
Beijing
2025-06-07
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy
NCT07257471Lung Cancer (NSCLC)
Beijing Haidian Hospital
Observational
30
Beijing
2025-06-06
Recruiting
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
NCT07446491Thrombocytopenia Associated With Chronic Liver Disease
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1/2
54
Beijing, Chongqing, Guangzhou, Zhengzhou, Zhenjiang, Changchun, Chaozhou, Qingdao
2025-06-06
Active, closed
Shared Medical Appointment for COPD Patients (SMA-COPD)
NCT07128745Chronic Obstructive Pulmonary Disease, COPD
Peking University Third Hospital
Not applicable
280
Beijing
2025-06-05
Recruiting
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
NCT06917664Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor
China National Center for Cardiovascular Diseases
Phase 4
220
Beijing
2025-06-05
Recruiting
Timing and Outcomes of Recovery After intraCerebral Hemorrhage
NCT07166146Intracerebral Haemorrhage, Intracerebral Hemorrhage
Xuanwu Hospital, Beijing
Observational
500
Beijing
2025-06-04
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
DrugsBleximenib·Venetoclax
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Beijing, Guangzhou, Wuhan
2025-06-04
Recruiting
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990Atopic Dermatitis (AD)
DrugLT-002-158
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Phase 1/2
24
Beijing
2025-06-04
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
DrugAZD0780
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Recruiting
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
NCT07014826Primary IgA Nephropathy
DrugHRS-5965
Chengdu Suncadia Medicine Co., Ltd.
Phase 3
378
Beijing
2025-06-04
Not yet open
A Population-based Cohort of Osteoarthritis: the Tsinghua University Tiantongyuan Community Osteoarthritis Study
NCT07006701Osteoarthritis
Beijing Tsinghua Chang Gung Hospital
Observational
4,000
Beijing
2025-06-03
Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy
Peking University People's Hospital
Observational
200
Beijing
2025-06-03
Active, closed
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
NCT07094464TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Daihong Liu
Phase 1
20
Beijing
2025-06-01
Active, closed
Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain
NCT06344403Herpes Zoster, Local Infiltration, Acute Pain
Beijing Tiantan Hospital
Not applicable
136
Beijing
2025-06-01
Recruiting
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT07040098Locally Advanced Rectal Cancer (LARC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
228
Beijing, Shenzhen
2025-06-01
Recruiting
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
NCT07015138Prostate Cancer, Oligometastatic Prostate Cancer
Peking University First Hospital
Not applicable
390
Beijing
2025-06-01
Recruiting
A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery
NCT07378683Surgical Site Infection (SSI), Central Nervous System Tumor
Ming Yang
Not applicable
500
Beijing
2025-06-01
Recruiting
68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
NCT07331532Breast Neoplasmsใ€Lung Neoplasmsใ€Pancreatic Neoplasms
Peking University First Hospital
Observational
10
Beijing
2025-06-01
By invitation
A Clinical Study on the Use of the Sentinel Cerebral Protection Device During TAVR for the Prevention of Procedure-Related Stroke
NCT07045233Stroke, Transcatheter Aortic Valve Replacement (TAVR), Aortic Stenosis Treated With TAVI
China National Center for Cardiovascular Diseases
Observational
200
Beijing
2025-06-01
Recruiting
Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion
NCT07611266Colorectal Cancer Control and Prevention
Beijing Friendship Hospital
Observational
3,000
Beijing
2025-06-01
Recruiting
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )
NCT07340723GVHD,Acute, Stem Cell Transplant Complications
DrugRuxolitinib
Daihong Liu
Phase 2
168
Beijing
2025-06-01
Recruiting
Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)
NCT07400549Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia
China National Center for Cardiovascular Diseases
Not applicable
100
Beijing
2025-06-01
Not yet open
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
NCT07007728Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver
DrugsCapeox·Iparomlimab and Tuvonralimab·Bevacizumab
Peking University Cancer Hospital & Institute
Phase 2
54
Beijing
2025-06-01
Not yet open
A Multi-Center Study on the Clinical Advantages of Personalized Total Knee Arthroplasty System
NCT07003035Osteoarthritis
YujiakuoTHU
Observational
80
Beijing
2025-06-01
Recruiting
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
NCT07537738Acute Myeloid Leukemia (AML), MLL Rearrangement
Peking University People's Hospital
Observational
210
Beijing
2025-06-01
Recruiting
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
NCT07109765Hidradenitis Suppurativa (HS)
DrugSecukinumab
Peking Union Medical College
Observational
50
Beijing
2025-06-01
Recruiting
Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients
NCT07001943Intestinal Ischemia, Critical Illness, Enteral Nutrition Feeding, Hemodynamics
Peking Union Medical College Hospital
Observational
80
Beijing
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis
NCT06990594Osteoarthritis
Beijing Tsinghua Chang Gung Hospital
Observational
120
Beijing
2025-06-01
Recruiting
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
NCT07053462End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Phase 1/2
90
Beijing
2025-06-01
Recruiting
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
NCT07034742Gastric Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
136
Beijing
2025-06-01
Recruiting
Prospective Multicenter Registry Study of Multiple System Atrophy in China
NCT07644013Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism
Peking University First Hospital
Observational
214
Beijing
2025-06-01
Not yet open
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
NCT06986538Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
1,064
Beijing, Fuzhou, Guangzhou, Qingyuan, Shaoguan, Zhaoqing, Nanning, Guiyang
2025-06-01
Not yet open
Acupuncture for Painful Temporomandibular Disorder
NCT06738667Temporomandibular Disorders (TMD)
Beijing Hospital of Traditional Chinese Medicine
Not applicable
48
Beijing
2025-06-01
Recruiting
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT07022964T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital
Phase 1/2
36
Beijing, Shanghai
2025-06-01
Recruiting
EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
NCT07450391Epstein-Barr Virus-Associated Lymphoproliferative Disorders, EBV-Positive Lymphoma
Daihong Liu
Phase 1/2
18
Beijing
2025-06-01
Recruiting
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
NCT07679399Biliary Tract Neoplasms Immunotherapy
DrugCapecitabine
Peking Union Medical College Hospital
Phase 2
222
Beijing
2025-06-01
Recruiting
Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG
NCT07172620Coronary Artery Bypass Grafting, Off-pump Coronary Artery Bypass, Minimally Invasive Cardiac Surgery, Coronary Arterial Disease (CAD)
Peking University Third Hospital
Observational
260
Beijing
2025-06-01
Recruiting
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
NCT07368634Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder
Daihong Liu
Phase 1/2
18
Beijing
2025-06-01
Recruiting
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
NCT07053488Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Phase 1/2
90
Beijing
2025-06-01
Not yet open
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
NCT07004712Small Cell Lung Cancer
DrugAdebelizumab
Peking University Cancer Hospital & Institute
Phase 2
46
Beijing
2025-06-01
Not yet open
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT06970132Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2
102
Beijing
2025-06
Not yet open
Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers
NCT07031596Obesity and Obesity-related Medical Conditions
Peking Union Medical College Hospital
Not applicable
198
Beijing
2025-06
Recruiting
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
Beijing GoBroad Hospital
Phase 1
44
Beijing
2025-06
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
NCT06765733Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA
Beijing Tiantan Hospital
Phase EARLY_PHASE1
20
Beijing
2025-05-31
Not yet open
Prospective Randomized Controlled Trial of VR Cognitive Training in Reducing Postoperative Delirium in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery
NCT06999668Postoperative Delirium (POD), Cerebral Small Vessel Diseases
Peking University Third Hospital
Not applicable
416
Beijing
2025-05-31
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Beijing, Shanghai
2025-05-30
Recruiting
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND
NCT06954155Stroke
DrugTenecteplase
Beijing Tiantan Hospital
Phase 3
330
Beijing
2025-05-30
Not yet open
Arthroscopic Treatment of Rotator Cuff Tears
NCT06961318Rotator Cuff
Peking University Third Hospital
Observational
600
Beijing
2025-05-30
Recruiting
Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
NCT07087873Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System, MS (Multiple Sclerosis), NMOSD, Acute Disseminated Encephalomyelitis
Xuanwu Hospital, Beijing
Not applicable
128
Beijing
2025-05-30
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsChlorambucil·Tacabrutideg·Bendamustine·Methylprednisolone
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Recruiting
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
NCT07152288Paroxysmal Nocturnal Hemoglobinuria (PNH)
DrugHSK39297
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
24
Beijing
2025-05-29
Recruiting
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
NCT07066982Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing, Sarcoma,Soft Tissue
Essen Biotech
Phase 1/2
60
Beijing
2025-05-29
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
DrugsJS007·JS207
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy๏ผˆFIRMOST๏ผ‰
NCT07010419NSCLC, Adjuvant Treatment
DrugFurmonertinib
Allist Pharmaceuticals, Inc.
Phase 3
338
Beijing, Guangdong
2025-05-28
Recruiting
Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease
NCT06992804Alzheimer Disease
Xuanwu Hospital, Beijing
Phase EARLY_PHASE1
20
Beijing
2025-05-28
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
NCT06410131Solid Tumors
Sound Biopharmaceuticals Ltd.
Phase 1
68
Beijing
2025-05-27
Recruiting
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
NCT06395285ROSAH
DrugDF-003
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Phase 1
12
Beijing
2025-05-27
Recruiting
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
NCT06971094SMA - Spinal Muscular Atrophy
GeneCradle Inc
Phase 3
50
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
2025-05-27
Active, closed
SMCs With LVH Compared to HCM
NCT07006974Syndromic and Metabolic Cardiomyopathy, Cardiomyopathies
China National Center for Cardiovascular Diseases
Observational
165
Beijing
2025-05-27
Recruiting
Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
NCT07111364Deep Learning, Ultrasound, Bladder Cancer
Peking University First Hospital
Observational
400
Beijing
2025-05-27
Active, closed
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
NCT07032597Mid Face Volume Deficit
AbbVie
Phase 3
252
Beijing, Wuhan, Nanjing, Wuxi, Shanghai, Hangzhou
2025-05-26
Recruiting
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
NCT06963177Endometriosis-related Pain
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
200
Beijing
2025-05-26
Recruiting
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
NCT06943677Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
By invitation
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
NCT07188285Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc)
Peking University People's Hospital
Observational
500
Beijing
2025-05-25
Recruiting
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
NCT07267078Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2
45
Beijing
2025-05-25
Active, closed
A Study for the Evaluation of Efficacy and Safety of Proliaยฎ in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153Glucocorticoid-induced Osteoporosis
DrugsProlia·Denosumab
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
By invitation
XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation
NCT06936527Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation
NovaOnco Therapeutics Co., Ltd.
Phase 1/2
102
Beijing
2025-05-23
Recruiting
A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults
NCT07013097Lichen Simplex Chronicus
DrugPG-033
Prime Gene Therapeutics Co., Ltd.
Phase 1
52
Beijing
2025-05-23
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity
NCT07327684Insulin Resistance, Metabolic Syndrome
Peking Union Medical College Hospital
Not applicable
100
Beijing
2025-05-22
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Cisplatin·Carboplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
Liraglutide Treatment in Obese Infertile PCOS Women
NCT06742710PCOS, Obesity, Infertility
DrugMetformin
Peking University Third Hospital
Phase 4
890
Beijing
2025-05-22
Recruiting
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT06962800Primary Membranous Nephropathy
DrugsFelzartamab·Tacrolimus
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
NCT06984536Myelodysplastic Syndrome, Acute Leukemia
Peking University People's Hospital
Phase 2
40
Beijing
2025-05-21
Recruiting
Teclistamab in Previously Treated AL Amyloidosis
NCT06935162AL Amyloidosis
DrugTeclistamab
Peking Union Medical College Hospital
Phase 2
30
Beijing
2025-05-21
Recruiting
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
NCT06902350Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC)
Chipscreen Biosciences, Ltd.
Phase 1
102
Beijing, Changchun
2025-05-21
Rows per page Showing 2101–2200 of 5484
Previous 20 21 22 23 24 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=22

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.